3176 results for «358»

Filter By

3176 results

Assessment and management of patients with multivalvular disease involving the tricuspid valve

22 May 2025 – From EuroPCR 2025

Gain expertise on managing multivalvular disease involving the tricuspid valve by understanding diagnostic challenges, intervention indications, and associated pathophysiological factors. This session includes complex case studies focusing on combined valvular lesions and guideline limitations.

Assessment and management of patients with multivalvular disease involving the tricuspid valve

Role of coronary physiology in acute coronary syndrome patients

22 May 2025 – From EuroPCR 2025

Examine the role of coronary physiology in acute coronary syndrome patients, including plaque characteristics related to ACS risk, prognostic value of AngioIMR in STEMI, functional significance of lumen and plaque features, diagnostic accuracy of quantitative flow ratio, and the impact of adenosine administration routes on FFR...

Role of coronary physiology in acute coronary syndrome patients

Innovation to address unmet clinical needs in transcatheter valve therapies

22 May 2025 – From EuroPCR 2025

Discover innovations addressing unmet clinical needs in transcatheter valve therapies. This session shares case-based experiences including young aortic stenosis patients, mitral regurgitation with annular calcification, and severe tricuspid regurgitation with right ventricular dysfunction, alongside the latest advances in TAVI, TMVR, and tricuspid interventions.

Innovation to address unmet clinical needs in transcatheter valve therapies

What an interventional cardiologist should know about anti-thrombotics

22 May 2025 – From EuroPCR 2025

This session provides comprehensive knowledge on anti-thrombotic management for interventional cardiologists, emphasizing effective inhibition during acute STEMI, latest evidence implementation for high bleeding risk patients, and customization of dual antiplatelet therapy in patients with high thrombotic and low bleeding risks through clinical cases and evidence-based recommendations.

What an interventional cardiologist should know about anti-thrombotics

Procedural planning and risk stratification in multivessel PCI

22 May 2025 – From EuroPCR 2025

This session focuses on procedural planning and risk stratification in multivessel PCI, presenting data from the TALENT and FIRE trials, prognostic value of post-PCI physiological assessments, and an innovative study comparing large language models in managing complex interventional cardiology cases.

Procedural planning and risk stratification in multivessel PCI

The role of DCB in non-left main true bifurcations

22 May 2025 – From EuroPCR 2025

This session offers a detailed exploration of drug-coated balloon (DCB) use in non-left main true bifurcation lesions. Learn to define suitable lesion characteristics for provisional stenting, understand stepwise procedural strategies minimizing implanted material, and appreciate the role of intravascular imaging in assessing bifurcation complexity and optimizing...

The role of DCB in non-left main true bifurcations

What did we learn from my TAVI complications?

22 May 2025 – From EuroPCR 2025

Review critical lessons from TAVI complications, focusing on early identification and management of access site issues and acute coronary obstruction. Learn effective preventive actions and procedural strategies to minimize severe TAVI-related complications through detailed case discussions.

What did we learn from my TAVI complications?

Pharmacotherapy coronary interventions: new insights

22 May 2025 – From EuroPCR 2025

Stay abreast of new insights in pharmacotherapy for coronary interventions with a focus on optimizing patient outcomes. Topics include ticagrelor monotherapy in chronic coronary syndrome post-PCI, analysis of multiple events in high bleeding risk patients from the MASTER DAPT trial, effects of beta-blocker interruption in MI...

Pharmacotherapy coronary interventions: new insights

Clinical and technical factors for decision-making in treatment of left main coronary artery disease

22 May 2025 – From EuroPCR 2025

Delve into decision-making factors in treating left main coronary artery disease, particularly in challenging scenarios. This session discusses the application of new SOLACI guidelines, critical strategy reflections, and real-world cases illustrating optimal left main PCI approaches.

Clinical and technical factors for decision-making in treatment of left main coronary artery disease

Optimal use of cardiac imaging to plan and guide transcatheter LAA closure

22 May 2025 – From EuroPCR 2025

Optimize left atrial appendage (LAA) closure outcomes through expert use of cardiac imaging. This session details the role of various imaging modalities in pre-procedural planning, intraprocedural guidance, and post-procedural assessment. Gain practical insights on transesophageal echocardiography, computed tomography, intracardiac echocardiography, and their integration to enhance procedural...

Optimal use of cardiac imaging to plan and guide transcatheter LAA closure

Optimising TEER in challenging anatomies

22 May 2025 – From EuroPCR 2025

Optimize transcatheter edge-to-edge repair (TEER) strategies in challenging anatomies with focus on tricuspid valve interventions, recognition of multivalvular disease, and planning combined mitral and tricuspid TEER procedures. Case studies highlight feasibility challenges and dual valve repair approaches.

Optimising TEER in challenging anatomies

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Paola Redaelli

Author

Paola Redaelli
M. Pighi

Author

Michele Pighi
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!

29 Sep 2023

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian

Author

Vijay Kunadian
World Heart Day 2023

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
Didn’t find what you were looking for?